Previous 10 | Next 10 |
Natera (NASDAQ:NTRA): Q2 GAAP EPS of -$1.32 misses by $0.20. Revenue of $142.03M (+64.3% Y/Y) beats by $11.16M. Press Release For further details see: Natera EPS misses by $0.20, beats on revenue
Natera Reports Second Quarter 2021 Financial Results PR Newswire AUSTIN, Texas , Aug. 5, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended ...
Natera Announces Use of Signatera® as a Companion Diagnostic in GSK's Phase III ZEST Trial for Niraparib in Early-Stage Breast Cancer PR Newswire AUSTIN, Texas , Aug. 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cel...
Natera Announces Second Quarter 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , July 29, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its sec...
New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer 14th peer-reviewed Signatera paper with over 3,000 patients studied PR Newswire AUSTIN, Texas , July 28, 2021 /PRNewswire/ -- Natera,Inc....
New Publication Shows 96% Overall Survival Among Metastatic Colorectal Cancer Patients Who Test MRD-Negative with Signatera® After Surgery Data will be used to support submission to CMS for reimbursement, expanding Signatera's coverage beyond early-stage colorectal cancer ...
BlackJack3D/E+ via Getty Images Natera (NTRA) has priced its public offering of 4.5M shares of its common stock at $113.00/share. Underwriters' over-allotment is an additional 675K shares. Closing date is July 26. Morgan Stanley, Goldman Sachs, Cowen and SVB Leerink are acting as joint book-r...
Genetic test maker Natera has launched a follow-on public offering of $350M common shares.The company expects to grant a 30-day option for underwriters to buy another $52.5M of shares at the offer price. The pricing and other terms of the offering remain undisclosed.Natera expects its Q221 re...
Rasi Bhadramani/iStock via Getty Images After more than doubling in value over the past 12-month period, Natera ([[NTRA]] -6.3%) has lost more than a tenth of value today, recording its biggest one-day loss since mid-May. Announcing the preliminary Q2 2021 results on Monday, Natera said that ...
Natera's (NTRA) revenue and volume growth rate in Q2 2021 was the largest Y/Y growth in its history as a publicly traded company.Total revenues for the Q2 of 2021 are expected to be ~$138-$141M vs. consensus of $127.48M, which represents ~60% Y/Y growth.The Co. expects its product revenu...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...